MA53745A - Procédés de traitement de troubles myéloprolifératifs - Google Patents
Procédés de traitement de troubles myéloprolifératifsInfo
- Publication number
- MA53745A MA53745A MA053745A MA53745A MA53745A MA 53745 A MA53745 A MA 53745A MA 053745 A MA053745 A MA 053745A MA 53745 A MA53745 A MA 53745A MA 53745 A MA53745 A MA 53745A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- myeloproliferative disorders
- treating myeloproliferative
- treating
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862736349P | 2018-09-25 | 2018-09-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53745A true MA53745A (fr) | 2021-08-04 |
Family
ID=69953555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053745A MA53745A (fr) | 2018-09-25 | 2019-09-24 | Procédés de traitement de troubles myéloprolifératifs |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220031713A1 (fr) |
| EP (1) | EP3856189A4 (fr) |
| JP (2) | JP2022502491A (fr) |
| KR (2) | KR20250134004A (fr) |
| CN (1) | CN113286593A (fr) |
| AU (2) | AU2019349652A1 (fr) |
| BR (1) | BR112021005571A2 (fr) |
| CL (1) | CL2021000743A1 (fr) |
| EA (1) | EA202190751A1 (fr) |
| IL (1) | IL281589A (fr) |
| MA (1) | MA53745A (fr) |
| MX (1) | MX417799B (fr) |
| SG (1) | SG11202102982QA (fr) |
| WO (1) | WO2020068754A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY209349A (en) | 2018-09-25 | 2025-07-03 | Impact Biomedicines Inc | Methods of treating myeloproliferative disorders |
| US12559463B2 (en) | 2019-02-12 | 2026-02-24 | Impact Biomedicines Inc. | Crystalline forms of a JAK2 inhibitor |
| US20230181690A1 (en) * | 2020-04-13 | 2023-06-15 | Celgene Corporation | Methods for treating anemia using an actriib ligand trap and fedratinib |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090093009A1 (en) * | 2007-10-09 | 2009-04-09 | Sum Chan | Mass spectrometry method for measuring thiamine in body fluid |
| AU2010363329A1 (en) * | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| CN103608012A (zh) * | 2011-06-14 | 2014-02-26 | 诺华股份有限公司 | 在癌症如骨髓增殖性肿瘤治疗中的帕比司他与鲁索利替尼的组合 |
| US10155987B2 (en) * | 2012-06-12 | 2018-12-18 | Dana-Farber Cancer Institute, Inc. | Methods of predicting resistance to JAK inhibitor therapy |
| KR102242077B1 (ko) * | 2012-11-15 | 2021-04-20 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
| JP2016527305A (ja) * | 2013-08-08 | 2016-09-08 | ノバルティス アーゲー | Ｐｉｍキナーゼ阻害剤の組合せ |
| WO2015081127A2 (fr) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies pour le traitement de troubles myeloproliferatifs |
| KR20160090814A (ko) * | 2013-11-27 | 2016-08-01 | 노파르티스 아게 | Jak, cdk 및 pim의 억제제를 포함하는 조합 요법 |
| MY209349A (en) * | 2018-09-25 | 2025-07-03 | Impact Biomedicines Inc | Methods of treating myeloproliferative disorders |
-
2019
- 2019-09-24 MA MA053745A patent/MA53745A/fr unknown
- 2019-09-24 US US17/279,763 patent/US20220031713A1/en not_active Abandoned
- 2019-09-24 AU AU2019349652A patent/AU2019349652A1/en not_active Abandoned
- 2019-09-24 JP JP2021540379A patent/JP2022502491A/ja active Pending
- 2019-09-24 SG SG11202102982QA patent/SG11202102982QA/en unknown
- 2019-09-24 KR KR1020257029099A patent/KR20250134004A/ko active Pending
- 2019-09-24 KR KR1020217012183A patent/KR20210098957A/ko not_active Ceased
- 2019-09-24 EA EA202190751A patent/EA202190751A1/ru unknown
- 2019-09-24 BR BR112021005571-1A patent/BR112021005571A2/pt unknown
- 2019-09-24 CN CN201980070463.6A patent/CN113286593A/zh active Pending
- 2019-09-24 MX MX2021003182A patent/MX417799B/es unknown
- 2019-09-24 WO PCT/US2019/052607 patent/WO2020068754A1/fr not_active Ceased
- 2019-09-24 EP EP19867553.0A patent/EP3856189A4/fr active Pending
-
2021
- 2021-03-17 IL IL281589A patent/IL281589A/en unknown
- 2021-03-25 CL CL2021000743A patent/CL2021000743A1/es unknown
- 2021-12-23 US US17/560,389 patent/US20220133751A1/en not_active Abandoned
-
2024
- 2024-11-29 JP JP2024208059A patent/JP2025029028A/ja active Pending
-
2025
- 2025-06-30 AU AU2025204914A patent/AU2025204914A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025029028A (ja) | 2025-03-05 |
| CN113286593A (zh) | 2021-08-20 |
| MX2021003182A (es) | 2021-07-16 |
| SG11202102982QA (en) | 2021-04-29 |
| AU2019349652A1 (en) | 2021-05-13 |
| KR20250134004A (ko) | 2025-09-09 |
| EA202190751A1 (ru) | 2021-06-28 |
| EP3856189A4 (fr) | 2022-06-29 |
| EP3856189A1 (fr) | 2021-08-04 |
| AU2025204914A1 (en) | 2025-07-17 |
| BR112021005571A2 (pt) | 2021-06-29 |
| JP2022502491A (ja) | 2022-01-11 |
| CL2021000743A1 (es) | 2021-10-08 |
| IL281589A (en) | 2021-05-31 |
| MX417799B (es) | 2024-11-07 |
| US20220031713A1 (en) | 2022-02-03 |
| US20220133751A1 (en) | 2022-05-05 |
| KR20210098957A (ko) | 2021-08-11 |
| WO2020068754A1 (fr) | 2020-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53741A (fr) | Procédés de traitement de troubles myéloprolifératifs | |
| EP3389725A4 (fr) | Compositions et méthodes pour le traitement de maladies du système nerveux central | |
| EP3481387A4 (fr) | Methodes et compositions pour le traitement de troubles épileptiques | |
| EP3448875A4 (fr) | Compositions pour le traitement de maladies | |
| EP3448987A4 (fr) | Compositions pour le traitement de maladies | |
| EP3448504A4 (fr) | Traitement de stimulation cérébrale pour dépression | |
| EP3448398A4 (fr) | Compositions et méthodes pour le traitement de troubles cutanés | |
| EP3500289A4 (fr) | Procédés de traitement de la trachéobronchomalacie | |
| EP3340982A4 (fr) | Composés pour le traitement de troubles immunitaires et inflammatoires | |
| EP3341391A4 (fr) | Compositions et procédés pour le traitement de la douleur | |
| EP3331527A4 (fr) | Procédés de traitement de troubles du développement à l'aide de pipradrol | |
| EP2970317A4 (fr) | Composés pyrimido-diazépinone et procédés de traitement de troubles | |
| EP3500267A4 (fr) | Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs | |
| EP4045037C0 (fr) | Hétéroaryl-biphénylamines pour le traitement de maladies pd-l1 | |
| EP3433266A4 (fr) | Méthodes de traitement de troubles mitochondriaux | |
| EP3481958A4 (fr) | Procédés et compositions de traitement de troubles et de maladies impliquant rdh12 | |
| EP3727403A4 (fr) | Méthodes intracanalaires de traitement de troubles du sein | |
| EP3833340A4 (fr) | Compositions et procédés de traitement de la presbytie | |
| EP3313417A4 (fr) | Méthodes de traitement de troubles auto-immuns et allo-immuns | |
| EP3801768A4 (fr) | Méthodes de traitement de troubles du hyperprolifératifs malins | |
| MA44126A (fr) | Méthodes de traitement de maladies et troubles pulmonaires | |
| EP3621434A4 (fr) | Méthodes de traitement de troubles neuropsychiatriques | |
| EP3316887A4 (fr) | Inhibiteurs de gls1 pour le traitement de maladies | |
| EP3826650A4 (fr) | Méthodes de traitement de troubles neurologiques | |
| EP3697767A4 (fr) | Composés et procédés de traitement du cancer |